A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2000 by National Center for Research Resources (NCRR).
Recruitment status was Active, not recruiting
Information provided by:
National Center for Research Resources (NCRR)
First received: July 25, 2000
Last updated: June 23, 2005
Last verified: July 2000
Peripheral neuropathies cause weakness and sensory loss that can produce severe disability. Some neuropathies are immune-mediated and associated with antibodies. It has been postulated that Rituxan treatment may reduce the level of antibody production limiting the loss of muscle strength and hence improve activities of daily living. The purpose of this open-label study (all participants get Rituxan and not placebo) is to determine the safety and effectiveness of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies in those who have already been treated with one course of Rituxan. Subjects will be treated on the in-patient Clinical Research Center with Rituxan for two treatments one week a part and then individual treatments every 10 weeks for one year. The effectiveness of Rituxan will be followed by looking for increases in muscle strength and decreases in the serum IgM autoantibodies.
||Masking: Open Label
Primary Purpose: Treatment
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Diagnosis of characteristic peripheral neuropathy by appropriate history, physical examination, nerve conduction findings and serum autoantibodies.
- Serum anti-GM1 on anti-MAG antibodies present at high titers in serum, continued by testing in the neuromuscular clinical laboratory at Washington University.
No Contacts or Locations Provided
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 25, 2000
||June 23, 2005
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 11, 2014
Peripheral Nervous System Diseases
Nervous System Diseases
Physiological Effects of Drugs